<DOC>
	<DOCNO>NCT01718990</DOCNO>
	<brief_summary>Drug discovery take many year especially since study measure effectiveness depend clinical outcome like pulmonary function test hospitalization . This observational study design collect information , blood , bronchoalveolar lavage fluid people IPF . The people IPF follow 12 month collect biological sample record clinically relevant information . The goal study identify new molecular marker measurable reliable people IPF . It hop marker used future drug study significantly speed process find drug help .</brief_summary>
	<brief_title>Biomarker Discovery Novel Drug Development Idiopathic Pulmonary Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<criteria>age 35 80 year diagnosis IPF consensus criterion condition make patient unacceptable risk bronchoscopy presence significant coexist emphysema HRCT active cigarette smoking ( define smoking within last 6 month ) presence significant comorbidity felt limit life expectancy le 12 month . active listing lung transplantation inability provide inform consent</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>